Theranostic Ruthenium Polypyridine Nanoparticles for Targeted Chimera Delivery into Ovarian Cancer Cells

Efficient in vivo delivery of small interfering RNAs (siRNAs) to target cells is challenging in clinical applications. Ruthenium (II) polypyridyl complexes have been discovered as imaging theranostic and anticancer agents due to their photophysical and biological properties. However, the clinical implementation of ruthenium complexes is limited by cancer cell selectivity. This study presents a novel siRNA delivery nanoplatform by ruthenium polypyridine complex nanoparticles (RPNs). The EGFR RNA aptamer and Notch3 siRNA chimera-loaded RPNs showed superior RNAi effects against Notch3 gene compared to Lipofectamine. Also, RPN-chimera complexes exhibited significant in vivo antitumor effects against ovarian cancer, which exhibited much potential in future cancer imaging guided gene therapy.